1506 - Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with unresectable Stage IV urothelial cancer

Page last updated: 28 March 2018

Application Detail

Status

Withdrawn

Description of Medical Service

PD-L1 is expressed on the surface of tumour cells and immune cells in a broad range of cancer types, including urothelial cancer. PD-L1 aids cancers in evading detection